SCHEMBL2970394

SCHEMBL2970394

CSc1cccc(-c2ccc3[nH]c4c(c3c2)CN(c2ncc(C(=O)O)c(C)n2)CC4)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 2/20 0.44
BAZ2B Q9UIF8 6/20 0.38
MAPT P10636 4/20 0.36
ALDH1A1 P00352 4/20 0.36
CASP1 P29466 2/20 0.36
CASP7 P55210 2/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4D Q08499 1/20 0.36
GAA P10253 1/20 0.36
CFTR P13569 1/20 0.36
MPL P40238 1/20 0.36
GLA P06280 2/20 0.36
LMNA P02545 2/20 0.35
PABPC1 P11940 1/20 0.35
ATM Q13315 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GBA1 P04062 1/20 0.35
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2986272 0.88 SIRT2 (0.46) SIRT2BAZ2BMAPTALDH1A1CASP1
SCHEMBL2973482 0.87 SIRT2 (0.44) SIRT2BAZ2BMAPTALDH1A1CASP1
SCHEMBL2980535 0.86 SIRT2 (0.44) SIRT2BAZ2BMAPTALDH1A1CASP1
SCHEMBL2978681 0.86 SIRT2 (0.44) SIRT2BAZ2BMAPTALDH1A1CASP1
SCHEMBL2978359 0.85 DHODH (0.44) SIRT2BAZ2BALDH1A1KDM4EPOLB
SCHEMBL2980633 0.85 SIRT2 (0.43) SIRT2BAZ2BMAPTALDH1A1CASP1
SCHEMBL2975810 0.85 SIRT2 (0.42) SIRT2BAZ2BMAPTALDH1A1CASP1
SCHEMBL5374096 0.84 BAZ2B (0.51) SIRT2BAZ2B
SCHEMBL2966428 0.84 SIRT2 (0.40) SIRT2BAZ2BMAPTALDH1A1CASP1
SCHEMBL2981584 0.84 SIRT2 (0.40) SIRT2BAZ2BMAPTALDH1A1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772245-B2 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
EP-1851219-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE Miikana Therapeutics, Inc. (US) 2007-11-07 EP disclosed
US-20060199829-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. 2006-09-07 US disclosed
WO-2006088949-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE MIIKANA THERAPEUTICS, INC. (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199829-A1 Inhibitors of histone deacetylase HDAC1, HDAC2, HDAC11 SIRT2 28/4885BAZ2B 33/4885MAPT 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.